Clinical response and safety of upadacitinib for alopecia areata: A retrospective study

Published: 20 February 2025| Version 1 | DOI: 10.17632/33vx2pbv8z.1
Contributor:
Jiecheng Li

Description

Supplemental Figure 1 detailing the change of SALT score during the treatment. Supplemental Table 1 detailing characteristics of patients with alopecia areata treated with oral upadacitinib. Supplemental Table 2 detailing evaluation of AA severity, clinical improvement, and treatment response during upadacitinib administration.

Files

Categories

Alopecia Areata

Funding

National Natural Science Foundation of China

82373504 and 82073459

Licence